We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

47 hedge funds and large institutions have $50M invested in Tonix Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

487% more capital invested

Capital invested by funds: $8.53M → $50M (+$41.5M)

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

81% more funds holding

Funds holding: 26 → 47 (+21)

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

11.34% more ownership

Funds ownership: 7.56% → 18.9% (+11%)

Holders
47
Holders Change
+21
Holders Change %
+80.77%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
10
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.19M
2
Northern Trust
Northern Trust
Illinois
+$3.96M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.97M
4
State Street
State Street
Massachusetts
+$2.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.92M

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$878K
2
Millennium Management
Millennium Management
New York
-$733K
3
HF
HRT Financial
New York
-$486K
4
CIAM
Caitong International Asset Management
Hong Kong
-$405K
5
VF
Virtu Financial
New York
-$302K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
51
IFP Advisors
Florida
– -$1.52K -10,000 Closed
FIA
52
FNY Investment Advisers
New York
– -$19K -1,100 Closed
MCI
53
MRP Capital Investments
Georgia
– -$1.79K -100 Closed
1 2
3

TNXP Hedge Fund Activity: Q2 2025 in Review

47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2025, worth a combined $50M — up 487% from $8.53M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new TNXP positions and 6 closed out — a net gain of 21 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $9.19M. The largest seller was Royal Bank of Canada, cutting an estimated $878K.

  • 47 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2025, up from 26 in Q1 2025.
  • Funds reported $50M of Tonix Pharmaceuticals stock for Q2 2025, up 487% quarter-over-quarter.
  • 27 funds opened new Tonix Pharmaceuticals positions in Q2 2025 and 6 closed out, a net change of +21 holders.
  • The largest Tonix Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $9.19M added.
  • The largest Tonix Pharmaceuticals seller in Q2 2025 was Royal Bank of Canada, an estimated $878K sold.

Based on aggregated 13F filings for Q2 2025.